Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1782058 10.3389/fphar.2026.1782058 Correction Correction: Fatal adverse events associated with programmed cell death ligand 1 inhibitors: a systematic review and meta-analysis Wang et al. 10.3389/fphar.2026.1782058 Wang Xuewen 1 Visualization Formal Analysis Software Project administration Writing - original draft Data curation Methodology Conceptualization Wu Shijie 2 Formal Analysis Writing - original draft Data curation Visualization Methodology Chen Yaying 1 Writing - original draft Software Formal Analysis Data curation Visualization Shao Erqian 1 Software Writing - original draft Data curation Formal Analysis Zhuang Tingting 1 Data curation Writing - original draft Formal Analysis Lu Linbin 1 Formal Analysis Writing - original draft Software Data curation Chen Xiong 1 * Resources Funding acquisition Validation Supervision Conceptualization Writing - review and editing Department of Oncology, The 900th Hospital of the People’s Liberation Army Joint Service Support Force, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, China Department of Clinical Medicine, Fujian Medical University, Fuzhou, China Correspondence: Xiong Chen, zpccx81@163.com 17 02 2026 2026 17 1782058 06 01 2026 14 01 2026 05 02 2026 Copyright © 2026 Wang, Wu, Chen, Shao, Zhuang, Lu and Chen. 2026 Wang, Wu, Chen, Shao, Zhuang, Lu and Chen https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Fatal adverse events associated with programmed cell death ligand 1 inhibitors: a systematic review and meta-analysis by Wang X, Wu S, Chen Y, Shao E, Zhuang T, Lu L and Chen X (2020). Front. Pharmacol. 11:5. doi: 10.3389/fphar.2020.00005 PD-L1 inhibitors fatal adverse events incidence meta-analysis interstitial lung disease section-at-acceptance Drugs Outcomes Research and Policies

A correction has been made to section Methods, Statistical Methods. This sentence previously stated:

“The funnel plot and Egger or Begger’s tests were used to estimate the publication bias of this study (Egger et al., 1997).”

The corrected sentence appears below:

“The funnel plot and Egger tests were used to estimate the publication bias of this study (Egger et al., 1997).”

A correction has been made to section Results, Publication Bias. This sentence previously stated:

“However, there was no evidence to prove publication bias existed in this study based on Begger’s test (p = 0.57). Moreover, when 26 eligible studies and 44 ineligible ones were included in the analysis, there was a significant publication bias based on Begger’s test (p < 0.0001).”

The corrected sentence appears below:

“A publication bias existed in this study based on Egger test (p < 0.01).”

A correction has been made to section Discussion, Paragraph 2. The final sentence of the paragraph, appearing below, was removed:

“However, the inclusion of these studies would introduce substantial bias based on the Begger’s test (p < 0.0001).”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and Reviewed by: Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa